8 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 9 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Systemic Juvenile Idiopathic Arthritis: new trials by email Literature Review of Systemic Juvenile Idiopathic Arthritis trials Research Report on Systemic Juvenile Idiopathic Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis. Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-11-01 | 2026-09-29 | |
| Pulmonary Involvement in Children With Systemic JIA Systemic Juvenile Idiopathic Arthritis, Lung Diseases | Not yet recruiting | Assiut University | 30 | 2026-10-20 | 2026-10-20 | |
| Clinical Features and Treatment of Systemic JIA in Children Tocilizumab (Actemra®) - Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis | Not yet recruiting | Sohag University | 50 | 2026-10-01 | 2026-09-11 | |
| A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients Familial Mediterranean Fever, Still Disease | Recruiting | Novartis Pharmaceuticals | 160 | 2026-03-15 | 2026-06-09 | |
| Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection SSGJ-613, Placebo - Systemic Juvenile Idiopathic Arthritis, Periodic Fever Syndrome | Phase 1 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 34 | 2021-08-13 | 2021-08-30 |
| A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Baricitinib, Tocilizumab - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Active not recruiting | Eli Lilly and Company | 58 | 2020-02-12 | 2026-08-11 |
| Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA Canakinumab - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 19 | 2015-05-07 | 2019-09-13 |
| A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies canakinumab - Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | Phase 3 | Completed | Novartis Pharmaceuticals | 31 | 2014-11-03 | 2020-05-19 |
| An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) ACZ885, Canakinumab - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2013-01-01 | 2015-10-15 | |
| Ultrasonography in Juvenile Idiopathic Arthritis Ultrasonography - Juvenile Idiopathic Arthritis, Oligoarthritis, Polyarticular Juvenile Rheumatoid Arthritis | Completed | University of Aarhus | 95 | 2009-10-01 | 2012-03-22 | |
| An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. Canakinumab - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 270 | 2009-09-01 | 2019-03-26 |
| Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) Canakinumab, Placebo - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Terminated | Novartis Pharmaceuticals | 84 | 2009-07-01 | 2017-03-29 |
| Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) rilonacept (IL-1 Trap), Placebo - Systemic Juvenile Idiopathic Arthritis | Phase 1 | Completed | Regeneron Pharmaceuticals | 24 | 2005-11-01 | 2013-03-04 |
| Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) MRA(Tocilizumab) - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Completed | Chugai Pharmaceutical | 19 | 2004-11-01 | 2008-07-30 |
| Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) MRA(Tocilizumab) - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Completed | Chugai Pharmaceutical | 60 | 2004-07-01 | 2009-12-23 |
| Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) MRA(Tocilizumab), placebo - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Completed | Chugai Pharmaceutical | 56 | 2004-05-01 | 2008-07-30 |
Arthritis, Juvenile (16) · Arthritis (3) · Arthralgia (2) · Bronchiolitis Obliterans Syndrome (2) · Rheumatoid Arthritis, Systemic Juvenile (2) · Cryopyrin-Associated Periodic Syndromes (1) · Familial Mediterranean Fever (1) · Fever (1) · Lung Diseases (1) · Mevalonate Kinase Deficiency (1) · Still's Disease, Adult-Onset (1)
Autoimmune Diseases (16) · Connective Tissue Diseases (16) · Immune System Diseases (16) · Joint Diseases (16) · Musculoskeletal Diseases (16) · Rheumatic Diseases (16) · Skin and Connective Tissue Diseases (16) · Arthritis (13) · Pathological Conditions, Signs and Symptoms (3) · Respiratory Tract Diseases (3) · Signs and Symptoms (3) · Bronchial Diseases (2) · Bronchiolitis (2) · Bronchiolitis Obliterans (2) · Bronchitis (2)
canakinumab (5) · tocilizumab (5) · Ultrasonography (1) · baricitinib (1) · rilonacept (1)
Novartis Pharmaceuticals (6) · Chugai Pharmaceutical (3) · Assiut University (1) · Children's Hospital Medical Center, Cincinnati (1) · Eli Lilly and Company (1) · Regeneron Pharmaceuticals (1) · Sohag University (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1) · University of Aarhus (1)
France (4) · United States (4) · Argentina (3) · Belgium (3) · Brazil (3) · Israel (3) · Italy (3) · Poland (3) · Spain (3) · Switzerland (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Canada (2) · Denmark (2) · Germany (2)
Takahiro Kakehi (3) · Amira Gamal Mohammed, Master (1) · Sharat Chandra, MD (1)
PMID 18358927, PMID 24634205, PMID 24786929, PMID 26314396, PMID 30269054, PMID 23252526, PMID 23754188, PMID 28115015, PMID 32552266
2014 (1), 2017 (1), 2018 (1), 2023 (1)